Severe asthma clinical remission after biologic treatment with anti-IL4/IL13: A real-life experience
- 6 July 2023
- journal article
- research article
- Published by Elsevier in Respiratory Medicine
- Vol. 217, 107348
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trialsThe Lancet Respiratory Medicine, 2020
- Mepolizumab effectiveness and identification of super-responders in severe asthmaEuropean Respiratory Journal, 2020
- An expert consensus framework for asthma remission as a treatment goalJournal of Allergy and Clinical Immunology, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysisRespiratory Research, 2019
- Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCARespiratory Research, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013